End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29,400 KRW | +3.16% | +3.52% | +13.73% |
2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.51 for the current year.
- With regards to fundamentals, the enterprise value to sales ratio is at 1914.98 for the current period. Therefore, the company is undervalued.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Historically, the company has been releasing figures that are above expectations.
Ratings chart - Surperformance
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.73% | 167M | - | ||
+20.00% | 20.87B | B+ | ||
0.00% | 19.71B | - | - | |
+21.07% | 13.17B | A- | ||
-19.40% | 8.64B | A- | ||
+23.52% | 8B | B+ | ||
+13.68% | 6.16B | B | ||
-10.89% | 3.95B | B+ | ||
-16.17% | 3.87B | C- | ||
+0.61% | 3.87B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A092730 Stock
- Ratings NeoPharm CO., LTD.